Open Access
E3S Web Conf.
Volume 218, 2020
2020 International Symposium on Energy, Environmental Science and Engineering (ISEESE 2020)
Article Number 03037
Number of page(s) 5
Section Environmental Chemistry and Environmental Pollution Analysis and Control
Published online 11 December 2020
  1. Heidenreich, P.A. et al. Forecasting the impact of heart failure in the United States: a policy statement from the American Heart Association. Circ Heart Fail 6, 606-619(2013). [CrossRef] [Google Scholar]
  2. Yancy, C.W. et al. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/ American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 62, e147-239 (2013). [CrossRef] [PubMed] [Google Scholar]
  3. Owan, T.E. et al. Trends in prevalence and outcome of heart failure with preserved ejection fraction. N Engl J Med 355, 251-259(2006). [CrossRef] [PubMed] [Google Scholar]
  4. Mentz, R.J. et al. Noncardiac comorbidities in heart failure with reduced versus preserved ejection fraction. J Am Coll Cardiol 64, 2281-2293(2014). [CrossRef] [PubMed] [Google Scholar]
  5. Steinberg, B.A. et al. Trends in patients hospitalized with heart failure and preserved left ventricular ejection fraction: prevalence, therapies, and outcomes. Circulation 126, 65-75(2012). [CrossRef] [PubMed] [Google Scholar]
  6. Maron, B.J. et al. Contemporary definitions and classification of the cardiomyopathies: an American Heart Association Scientific Statement from the Council on Clinical Cardiology, Heart Failure and Transplantation Committee; Quality of Care and Outcomes Research and Functional Genomics and Translational Biology Interdisciplinary Working Groups; and Council on Epidemiology and Prevention. Circulation 113, 1807-1816(2006). [Google Scholar]
  7. McMurray, J.J. et al. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur Heart J 33, 1787-1847(2012). [CrossRef] [PubMed] [Google Scholar]
  8. Soman P. et al. Etiology and pathophysiology of new-onset heart failure: evaluation by myocardial perfusion imaging. J Nucl Cardiol 16, 82-91(2009). [CrossRef] [PubMed] [Google Scholar]
  9. Rau, C.D., Lusis, A.J. & Wang Y. Genetics of common forms of heart failure: challenges and potential solutions. Curr Opin Cardiol 30, 222-227(2015). [CrossRef] [PubMed] [Google Scholar]
  10. Hershberger, R.E. & Siegfried, J.D. Update 2011: clinical and genetic issues in familial dilated cardiomyopathy. J Am Coll Cardiol 57, 1641-1649(2011). [CrossRef] [PubMed] [Google Scholar]
  11. Bovelli, D., Plataniotis, G., Roila F. & Group, E.G.W. Cardiotoxicity of chemotherapeutic agents and radiotherapy-related heart disease: ESMO Clinical Practice Guidelines. Ann Oncol 21 Suppl 5, v277-282 (2010). [CrossRef] [PubMed] [Google Scholar]
  12. Carver, J.R., Szalda D. & Ky B. Asymptomatic cardiac toxicity in long-term cancer survivors: defining the population and recommendations for surveillance. Semin Oncol 40, 229-238(2013). [CrossRef] [PubMed] [Google Scholar]
  13. Kenchaiah S. et al. Obesity and the risk of heart failure. N Engl J Med 347, 305-313(2002). [CrossRef] [Google Scholar]
  14. Nichols, G.A., Gullion, C.M., Koro, C.E., Ephross, S.A. & Brown, J.B. The incidence of congestive heart failure in type 2 diabetes: an update. Diabetes Care 27, 1879-1884(2004). [CrossRef] [PubMed] [Google Scholar]
  15. Shindler, D.M. et al. Diabetes mellitus, a predictor of morbidity and mortality in the Studies of Left Ventricular Dysfunction (SOLVD) Trials and Registry. Am J Cardiol 77, 1017-1020(1996). [CrossRef] [PubMed] [Google Scholar]
  16. Horwich, T.B. & Fonarow, G.C. The impact of obesity on survival in patients with heart failure. Heart Fail Monit 3, 8-14(2002). [PubMed] [Google Scholar]
  17. Carbone, S., Lavie, C.J. & Arena R. Obesity and Heart Failure: Focus on the Obesity Paradox. Mayo Clin Proc 92, 266-279(2017). [CrossRef] [PubMed] [Google Scholar]
  18. Bojunga J. et al. Antioxidative treatment prevents activation of death-receptorand mitochondriondependent apoptosis in the hearts of diabetic rats. Diabetologia 47, 2072-2080(2004). [CrossRef] [PubMed] [Google Scholar]
  19. Williams, S.B. et al. Acute hyperglycemia attenuates endothelium-dependent vasodilation in humans in vivo. Circulation 97, 1695-1701(1998). [CrossRef] [PubMed] [Google Scholar]
  20. Karnik, A.A., Fields, A.V. & Shannon, R.P. Diabetic cardiomyopathy. Curr Hypertens Rep 9, 467-473(2007). [CrossRef] [PubMed] [Google Scholar]
  21. van Heerebeek, L. et al. Diastolic stiffness of the failing diabetic heart: importance of fibrosis, advanced glycation end products, and myocyte resting tension. Circulation 117, 43-51(2008). [CrossRef] [PubMed] [Google Scholar]
  22. Ferdinand, K.C. Isosorbide dinitrate and hydralazine hydrochloride: a review of efficacy and safety. Expert Rev Cardiovasc Ther 3, 993-1001(2005). [CrossRef] [Google Scholar]
  23. Carmody, M.S. & Anderson, J.R. BiDil (isosorbide dinitrate and hydralazine): a new fixed-dose combination of two older medications for the treatment of heart failure in black patients. Cardiol Rev 15, 46-53(2007). [CrossRef] [PubMed] [Google Scholar]
  24. Ide T. et al. Ivabradine for the Treatment of Cardiovascular Diseases. Circ J 83, 252-260(2019). [CrossRef] [PubMed] [Google Scholar]
  25. Thorup, L., Simonsen, U., Grimm D. & Hedegaard, E.R. Ivabradine: Current and Future Treatment of Heart Failure. Basic Clin Pharmacol Toxicol 121, 89-97 (2017). [CrossRef] [PubMed] [Google Scholar]
  26. Lee, W.C. & Fang, H.Y. Ivabradine for the Treatment of Acute Mitral – Regurgitation Related Decompensated Heart Failure. Cardiology 144, 97-100(2019). [CrossRef] [Google Scholar]
  27. Miller, S.E. & Alvarez, R.J.Jr,. Aldosterone antagonists in heart failure. J Cardiovasc Nurs 28, E47-54 (2013). [CrossRef] [PubMed] [Google Scholar]
  28. Pantelidis P. et al. The Mechanisms of Actions of Aldosterone and its Antagonists in Cardiovascular Disease. Curr Pharm Des 24, 5491-5499(2018). [CrossRef] [PubMed] [Google Scholar]
  29. Ambrosy, A.P. et al. The role of angiotensin receptorneprilysin inhibitors in cardiovascular diseaseexisting evidence, knowledge gaps, and future directions. Eur J Heart Fail 20, 963-972(2018). [CrossRef] [PubMed] [Google Scholar]
  30. Bramblett, T., Teleb, M., Albaghdadi, A., Agrawal H. & Mukherjee D. Heart Failure with Preserved Ejection Fraction: Entresto a Possible Option. Cardiovasc Hematol Disord Drug Targets 17, 80-85(2017). [CrossRef] [PubMed] [Google Scholar]
  31. Deedwania, P.C. & Carbajal E. Evidence-based therapy for heart failure. Med Clin North Am 96, 915-931(2012). [CrossRef] [PubMed] [Google Scholar]
  32. Nochioka, K., Sakata Y. & Shimokawa H. Combination Therapy of Renin Angiotensin System Inhibitors and beta-Blockers in Patients with Heart Failure. Adv Exp Med Biol 1067, 17-30(2018). [CrossRef] [PubMed] [Google Scholar]
  33. Katbeh A. et al. Cardiac Resynchronization Therapy Optimization: A Comprehensive Approach. Cardiology 142, 116-128(2019). [CrossRef] [Google Scholar]
  34. Naqvi, S.Y., Jawaid, A., Goldenberg I. & Kutyifa V. Non-response to Cardiac Resynchronization Therapy. Curr Heart Fail Rep 15, 315-321(2018). [CrossRef] [PubMed] [Google Scholar]
  35. Tschope C. et al. Cardiac contractility modulation: mechanisms of action in heart failure with reduced ejection fraction and beyond. Eur J Heart Fail 21, 14-22 (2019). [CrossRef] [PubMed] [Google Scholar]
  36. Gerson, M.C., Abdallah, M., Muth, J.N. & Costea, A.I. Will imaging assist in the selection of patients with heart failure for an ICD? JACC Cardiovasc Imaging 3, 101-110(2010). [CrossRef] [PubMed] [Google Scholar]
  37. van der Ende, M.Y., Said, M.A., van Veldhuisen, D.J., Verweij N. & van der Harst P. Genome-wide studies of heart failure and endophenotypes: lessons learned and future directions. Cardiovasc Res 114, 1209-1225 (2018). [PubMed] [Google Scholar]

Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.

Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.

Initial download of the metrics may take a while.